Zinc Oxide
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Zinc Oxide: From Topical Skin Protectant to Acne
One-Sentence Summary
Zinc oxide (DrugBank DB09321) is a long-established topical agent; no formal original indication or SAHPRA registration is recorded in this dataset. The TxGNN model predicts it may be effective for Acne (Acne vulgaris), with 0 clinical trials and 7 publications currently supporting this direction — evidence remains at the mechanistic/observational level, with no RCTs identified.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in this dataset (no SAHPRA license on file) |
| Predicted New Indication | Acne (Acne vulgaris) |
| TxGNN Prediction Score | 99.86% |
| Evidence Level | L3 |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Proceed with Guardrails |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available for zinc oxide in this dataset (flagged as a High-severity data gap). Based on known pharmacology, zinc oxide applied topically has antibacterial activity against Cutibacterium acnes, anti-inflammatory effects, and a modulating action on sebum production — properties consistent with its long history of use as a topical dermatological agent.
Acne vulgaris is a chronic inflammatory disease of the pilosebaceous unit, and the antibacterial/anti-inflammatory profile of topical zinc oxide is mechanistically well aligned with this pathology. Several published reviews already discuss zinc-based formulations (including zinc oxide) as adjunct or alternative therapy in acne management, particularly as a lower-irritant alternative to retinoids and antibiotics.
That said, the supporting literature in this evidence pack consists of reviews, a cohort study, and preclinical/formulation reports — no randomized controlled trials evaluating zinc oxide specifically for acne were identified. The mechanistic rationale is reasonable, but clinical-grade confirmatory evidence is still lacking.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 29193602 | 2018 | Review | Dermatologic Therapy | Reviews the role of zinc (including zinc oxide) in acne treatment as an adjunct to standard topical/systemic therapy, noting a favorable tolerability profile compared to conventional agents. |
| 21342155 | 2011 | Review | International Journal of Dermatology | Discusses zinc oxide and titanium dioxide nanoparticles as novel treatments under investigation for acne vulgaris and other dermatologic conditions. |
| 15536660 | 2004 | Cohort | Skin Research and Technology | Split-face clinical/bioinstrumental assessment of mild inflammatory catamenial acne; explores adjunct topical management strategies. |
| 36888703 | 2023 | Preclinical/Device | Science Advances | Zinc porphyrin-based nanoparticle microneedle patch for ultrasound-triggered treatment of bacterial (P. acnes) acne infection. |
| 31322532 | 2019 | Formulation Development | Georgian Medical News | Development of powder-based cosmetic/cosmeceutical formulas for acne management. |
| 29284390 | 2018 | Preclinical | Current Medicinal Chemistry | Reviews ultrasonic functionalization of textiles with reactive nanomaterials, including zinc-based coatings, for wound and acne-prone skin care. |
| 41033952 | 2025 | Basic Science | Science Bulletin | ZnO-based piezoelectric heterojunction material for pathogen-responsive modulation of skin microbiota, targeting Cutibacterium acnes. |
South Africa Market Information
Zinc oxide has no SAHPRA registration on file in this dataset (0 licenses; market status: Not marketed). Formal South African product and indication data will need to be sourced directly from SAHPRA before further evaluation.
Safety Considerations
Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.
Conclusion and Next Steps
Decision: Proceed with Guardrails
Rationale: The mechanistic rationale for zinc oxide in acne is plausible and supported by multiple reviews and an observational cohort study (Evidence Level L3), but no clinical trials or RCTs specific to this indication were identified, and safety/regulatory data are currently missing.
To proceed, the following is needed:
- SAHPRA-approved Professional Information (warnings, contraindications) — currently a Blocking data gap preventing safety pre-assessment
- Formal mechanism of action (MOA) documentation from DrugBank or equivalent source
- Prospective clinical trial evidence (ideally RCT) evaluating zinc oxide specifically for acne
- Confirmation of South African registration/market status for any zinc oxide product intended for this indication
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.